Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2024

Why neoadjuvant immunotherapy is the future for melanoma

Conclusions and perspectives

Date

13 Sep 2024

Session

Why neoadjuvant immunotherapy is the future for melanoma

Topics

Tumour Immunology

Tumour Site

Melanoma

Presenters

Christian Blank

Authors

C.U. Blank

Author affiliations

  • Medical Oncology Dept, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Basic science rationale

Presenter: Sapna Patel

Session: Why neoadjuvant immunotherapy is the future for melanoma

Resources:

Slides

Webcast

Summary of clinical trials so far

Presenter: Paolo Ascierto

Session: Why neoadjuvant immunotherapy is the future for melanoma

Resources:

Slides

Webcast

Which patients need surgery?

Presenter: Alexander van Akkooi

Session: Why neoadjuvant immunotherapy is the future for melanoma

Resources:

Slides

Webcast

Q&A and discussion

Session: Why neoadjuvant immunotherapy is the future for melanoma

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.